Authors
Loading...
CARM1 mediates MAP2K4 methylation, influencing oncogenic activity in triple-negative breast cancer cells, suggesting a new treatment target.
Kim et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: